BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15865848)

  • 1. Clinical value of fulvestrant in breast cancer.
    Gradishar WJ
    Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S4. PubMed ID: 15865848
    [No Abstract]   [Full Text] [Related]  

  • 2. Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?
    Howell A
    Int J Gynecol Cancer; 2006; 16 Suppl 2():521-3. PubMed ID: 17010063
    [No Abstract]   [Full Text] [Related]  

  • 3. Fulvestrant antiestrogen for treatment of breast cancer.
    Hancock CM
    Clin J Oncol Nurs; 2003; 7(2):201-2. PubMed ID: 12696217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.
    Jones SE
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):14-20. PubMed ID: 14613022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.
    Frassoldati A; Guarneri V; Conte P
    Cancer Biol Ther; 2009 Aug; 8(15):1456-8. PubMed ID: 19617703
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment for advanced breast cancer.
    FDA Consum; 2002; 36(4):6. PubMed ID: 12184311
    [No Abstract]   [Full Text] [Related]  

  • 8. A new estrogen receptor antagonist--an overview of available data.
    Jones SE
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant - a novel endocrine therapy for breast cancer.
    Johnston SJ; Cheung KL
    Curr Med Chem; 2010; 17(10):902-14. PubMed ID: 20156170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant and the sequential endocrine cascade for advanced breast cancer.
    Johnston S
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S15-8. PubMed ID: 15094760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
    Chan S
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):129-33. PubMed ID: 12138407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
    Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
    Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
    Oakman C; Moretti E; Santarpia L; Di Leo A
    Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of fulvestrant in the management of postmenopausal breast cancer.
    Krell J; Januszewski A; Yan K; Palmieri C
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1641-52. PubMed ID: 22050013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in endocrine therapy of metastatic breast cancer.
    Gradishar WJ; Morrow M
    Br J Surg; 2002 Dec; 89(12):1489-92. PubMed ID: 12445055
    [No Abstract]   [Full Text] [Related]  

  • 17. Fulvestrant and male breast cancer: a case series.
    Zagouri F; Sergentanis TN; Chrysikos D; Zografos E; Rudas M; Steger G; Zografos G; Bartsch R
    Ann Oncol; 2013 Jan; 24(1):265-6. PubMed ID: 23251011
    [No Abstract]   [Full Text] [Related]  

  • 18. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
    Chia S; Gradishar W
    Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
    Jones SE; Pippen J
    Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S9-14. PubMed ID: 15865850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
    Buzdar AU
    Drugs Today (Barc); 2008 Sep; 44(9):679-92. PubMed ID: 19137123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.